CorMedix Inc.
CRMDHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. The company carries a $660.6M market cap, placing it firmly in the small-cap category. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Market Cap
$660.6M
Beta
1.46
P/E (TTM)
3.88
P/E (Fwd)
24.06
EPS (TTM)
$2.17
EPS (Fwd)
$0.35
ROE
65.6%
ROA
26.4%
Cash
$178.1M
Total Debt
$147.4M
Free CF
$119.8M
52W Change
-30.6%
Annual Financials
Cash vs Debt
With $178.1M in cash and $147.4M in debt, CRMD maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $119.8M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 65.6%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 26.4% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $191K to $311.7M.
As with any equity investment, CRMD carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CRMD.